U.S. Events Finder

See what sports, music or family events are going on there. We show you events of all kinds: make your selection from the right-hand navigation bar. After you make your selection, please click Apply button.

Music

Performing

Media

Social

Education

Commercial

Festivals

Sports

Other

Comedy

Politics

Family

Conference

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

Pharmacogenomics

Nov 19-22, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

This meeting will focus on the opportunities presented by the growing contribution of emerging genomic information and technologies to interdisciplinary approaches in the study of variable responses of humans to drugs and toxic agents, and how research may benefit the individual. The meeting will provide an in depth focus on diverse areas including the biochemistry and physiology of drug action, uptake and metabolism, and how this is affected by genetics; the opportunities for discovery and design of new therapeutic agents; personalizing medicine; understanding and managing adverse drug reactions; the impact of academic and commercial initiatives; ethical, legal, regulatory and social consequences of genetics applied to medicines. The meeting will include two sessions devoted to major global pharmacogenomics research initiatives. These sessions are intended to highlight recent advances in global pharmacogenomics research and to stimulate collaborations through sample sharing and data/knowledge sharing.

Neurodegenerative Diseases: Biology & Therapeutics

Dec 4-7, 2008 at Cold Spring Harbor Laboratory, Cold Spring Harbor New York United States

Rational drug discovery for neurodegenerative diseases has begun to yield compounds and approaches which are entering the clinic. In order for these human studies to yield a maximum of information and success, it is now more crucial than ever for scientists from academia and industry to have forums for the exchange of data and ideas. This meeting will consist of six to seven sessions, each of which will be composed of one talk by the session chair, one talk by an invited speaker, and several additional talks selected from the submitted abstracts. It is expected that half of the session chairs and speakers (invited and from submitted abstracts) will be from each "sector": i.e., half from academia and half from industry.

U.S. States

• Montana
• Maryland
• Michigan
• Arkansas
• Kentucky
• Virginia
• Puerto Rico
• Iowa

View all States in USA

Cities in New York

• Sidney Center (NY)
• Newfield (NY)
• Cassville (NY)
• South Plymouth (NY)
• Naples (NY)
• Hilton (NY)
• Malden Bridge (NY)
• Mc Graw (NY)

View all cities in New York

States in USA

Hide States

Cities in New York

Hide Cities